Based on the results of our study, further clinical studies should focus on the efficacy and safety of anti-PD-L1 ICIs combined with chemotherapy in extensive-stage SCLC patients of female sex, ethnic groups other than East Asian, and those from different geographic areas. This evidence concerns the gene CD274 and small cell lung carcinoma.